ImageneBio, Inc. (IMA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $5.68. The rating moved from Overbought to Oversold on August 18, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$5.68
• Last changeMoved from Overbought to Oversold on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

ImageneBio, Inc. exhibits typical small‑cap biotech characteristics: upside tied to binary clinical and partnership milestones and downside from financing and clinical/regulatory risk. Broader sector themes (diagnostic demand and growth bias in equities) provide a constructive backdrop, but company‑specific visibility is limited due to a lack of recent filings or social/research signals. Near‑term price action will likely track headline catalysts and liquidity; medium‑term outcomes depend on data readouts, capital raises, or partnership developments.

Key factors

• Small-cap biotechnology profile with typical binary, milestone-driven value drivers (clinical data, partnerships, regulatory actions).
• Sector tailwinds for diagnostics and screening (oncology/CRC) could benefit companies with relevant programs or partnerships.
• Current market environment is mildly risk-on, which tends to favor growth/biotech sentiment in the near term.
• Limited company-specific public disclosures and no recent EDGAR comparison provided, increasing uncertainty about financial runway and near-term catalysts.
• Potential strategic benefit from broader healthcare trends (AI/data analytics, biologics CDMO demand) if the company has relevant assets or partners.

Risks

• Clinical or regulatory setbacks typical for biotech that can cause sharp share price declines.
• Dilution risk from future equity raises if cash runway is limited or operating losses continue.
• Low trading liquidity and wide bid/ask spreads increasing volatility and execution risk for investors.
• Reimbursement, commercialization, or competitive risks if programs move toward market.
• Lack of clear, recent company-specific news or financial filings creates information asymmetry and forecast risk.

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.